Prise en charge de la maladie du greffon contre l'hôte chronique : Recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)
Prise en charge de la maladie du greffon contre l'hôte chronique : Recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)
Alternative titles :
[en] Management of the chronic graft versus host disease: Guidelines from the Francophone society of bone marrow transplantation and cellular therapies (SFGM-TC)
Filipovich, A.H., Weisdorf, D., Pavletic, S., Socie, G., Wingard, J.R., Lee, S.J., et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11:12 (2005), 945–956.
Couriel, D.R., Hosing, C., Saliba, R., Shpall, E.J., Anderlini, P., Rhodes, B., et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 107:8 (2006), 3074–3080.
Flowers, M.E., Martin, P.J., How we treat chronic graft-versus-host disease. Blood 125:4 (2015), 606–615.
Koreth, J., Kim, H.T., Jones, K.T., Lange, P.B., Reynolds, C.G., Chammas, M.J., et al. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood 128:1 (2016), 130–137.
Magro, L., Catteau, B., Coiteux, V., Bruno, B., Jouet, J.P., Yakoub-Agha, I., Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD. Bone Marrow Transplant 42:11 (2008), 757–760.
Magro, L., Gauthier, J., Richet, M., Robin, M., Nguyen, S., Suarez, F., et al. Scleral lenses for severe chronic GvHD-related keratoconjunctivitis sicca: a retrospective study by the SFGM-TC. Bone Marrow Transplant 52:6 (2017), 878–882.
Magro, L., Mohty, M., Catteau, B., Coiteux, V., Chevallier, P., Terriou, L., et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood 114:3 (2009), 719–722.
Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S.K., et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 29:10 (2015), 2062–2068.
Carpenter, P.A., Kitko, C.L., Elad, S., Flowers, M.E., Gea-Banacloche, J.C., Halter, J.P., et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. The 2014 ancillary therapy and supportive care working group report. Biol Blood Marrow Transplant 21:7 (2015), 1167–1187.
Lee, S.J., Wolff, D., Kitko, C., Koreth, J., Inamoto, Y., Jagasia, M., et al. Measuring therapeutic response in chronic graft-versus-host disease. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 response criteria working group report. Biol Blood Marrow Transplant 21:6 (2015), 984–999.
Shulman, H.M., Cardona, D.M., Greenson, J.K., Hingorani, S., Horn, T., Huber, E., et al. NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 pathology working group report. Biol Blood Marrow Transplant 21:4 (2015), 589–603.
Jagasia, M.H., Greinix, H.T., Arora, M., Williams, K.M., Wolff, D., Cowen, E.W., et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant, 21(3), 2015 389-401 e1.
Greinix, H.T., Loddenkemper, C., Pavletic, S.Z., Holler, E., Socie, G., Lawitschka, A., et al. Diagnosis and staging of chronic graft-versus-host disease in the clinical practice. Biol Blood Marrow Transplant 17:2 (2010), 167–175.
Tipton, R., Yakoub-Agha, I., [How we harmonize HSCT clinical practices among the SFGM-TC centers]. Bull Cancer 103:11S (2016), S193–S197.
Moon, J.H., Sohn, S.K., Lambie, A., Ellis, L., Hamad, N., Uhm, J., et al. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival. Biol Blood Marrow Transplant 20:4 (2014), 556–563.
Inamoto, Y., Martin, P.J., Chai, X., Jagasia, M., Palmer, J., Pidala, J., et al. Clinical benefit of response in chronic graft-versus-host disease. Biol Blood Marrow Transplant 18:10 (2012), 1517–1524.
Wolff, D., Gerbitz, A., Ayuk, F., Kiani, A., Hildebrandt, G.C., Vogelsang, G.B., et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 16:12 (2010), 1611–1628.
Rubio, M.T., Charbonnier, A., de Berranger, E., Gandemer, V., Magro, L., Maury, S., et al. [Vaccination post-hematopoietic stem cell transplantation: which vaccines and when and, how to vaccinate? An SFGM-TC report]. Pathol Biol (Paris) 61:4 (2013), 139–143.
Vantyghem, M.C., Cornillon, J., Decanter, C., Defrance, F., Karrouz, W., Leroy, C., et al. Management of endocrino-metabolic dysfunctions after allogeneic hematopoietic stem cell transplantation. Orphanet J Rare Dis, 9, 2014, 162.
Cornillon, J., Decanter, C., Couturier, M.A., de Berranger, E., Francois, S., Hermet, E., et al. [Management of endocrine dysfunctions after allogeneic hematopoietic stem cell transplantation: a report of the SFGM-TC on gonadal failure and fertility]. Pathol Biol (Paris) 61:4 (2013), 164–167.
Cornillon, J., Vantyghem, M.C., Couturier, M.A., de Berranger, E., Francois, S., Hermet, E., et al. [Management of endocrine dysfunctions after allogeneic hematopoietic stem cell transplantation: a report of the SFGM-TC on dyslipidemia and thyroid disorders]. Pathol Biol (Paris) 61:4 (2013), 168–170.
Cornillon, J., Vantyghem, M.C., Couturier, M.A., de Berranger, E., Francois, S., Hermete, E., et al. [Management of endocrine dysfunctions after allogeneic hematopoietic stem cell transplantation: a report of the SFGM-TC on adrenal insufficiency and osteoporosis]. Pathol Biol (Paris) 61:4 (2013), 171–173.
Jaspers, A., Bouhya, S., Belaiche, S., Chevallier, P., Hermet, E., Hospital-Gustems, C., et al. [Assessment and management of post-transplant iron overload: Guidelines of the Francophone society of marrow transplantation and cellular therapy (SFGM-TC)]. Bull Cancer 103:11S (2016), S255–S266.
